Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.

Jones Day
Contact

Jones Day

On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19 pandemic, with the Japanese government increasingly focused on maintaining domestic production capabilities in key life science industries to protect national security and the health and safety of its people.

Under FEFTA, a foreign investor in a Japanese company is generally required to submit a notification to the government with respect to the acquisition of (i) one percent or more of the shares in a listed Japanese company or (ii) any shares in an unlisted Japanese company. However, if the target Japanese company includes a Designated Business, then the foreign investor must submit a notification prior to the acquisition and the acquisition will be subject to a 30-day waiting period, during which the government may review and raise objections to the planned investment. Moreover, while several exemptions to this prior notification requirement are available for passive investments in Designated Businesses, if the Designated Business is also classified as a Core Business, like the life science businesses at issue here, most of those exemptions will not apply.

These new regulations will apply to foreign direct investments that are made on or after July 15, 2020. As a result of the new regulations, many foreign investments in Japanese life science companies, even including passive investments, may be newly subject to the prior notification and review requirement under FEFTA, and potential investors should consider this regulation carefully before moving forward with any proposed investments in the Japanese life sciences sector.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Jones Day | Attorney Advertising

Written by:

Jones Day
Contact
more
less

Jones Day on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.